文献速递肿瘤 PET/CT放射性药物与辐射防护

124I标记特瑞普利单抗用于癌症患者PD-1表达PET成像的首次人体临床转化研究

Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该首次人体研究纳入8例黑色素瘤和3例泌尿系统肿瘤患者,使用124I-JS001进行PET/CT和PET/MR成像,评估其生物分布、安全性和剂量学。结果显示该示踪剂安全、剂量学可接受,所有肿瘤病灶均有不同程度摄取,PET/MR对肝病灶检测比PET/CT更敏感。

要点

  • 124I-JS001安全,未观察到不良事件,剂量学为0.236 mSv/MBq。
  • 所有原发和转移灶均有摄取,SUVmax范围0.2–4.7。
  • 共注射未标记JS001后脾摄取显著降低,肿瘤摄取和靶本比显著增加(P<0.05)。

核心结论

  • 124I-JS001是安全的PET示踪剂,剂量学可接受,生物分布良好。
  • PET/MR检测肝病灶比PET/CT更敏感。

研究设计与样本

  • 纳入病理确诊的黑色素瘤或泌尿系统肿瘤患者,进行124I-JS001 PET/CT和PET/MR(伴或不伴5 mg未标记JS001共注射)以及18F-FDG PET。

主要发现

  • 8例黑色素瘤和3例泌尿系统肿瘤患者入组,注射后未观察到不良事件。
  • 124I-JS001 PET/CT显示脾和肝高摄取,骨髓和肺轻微摄取。
  • 11例患者所有原发和转移灶均有不同程度124I-JS001摄取,SUVmax 0.2–4.7。
  • 共注射未标记JS001后脾摄取显著降低(P<0.05),肿瘤摄取和靶本比显著增加(P<0.05)。
  • 4例患者进行局部124I-JS001 PET/MR,所有肿瘤病灶均有效检测到异常MR信号,PET/MR检测肝病灶比PET/CT更敏感。

关键数值与推荐

  • 剂量学为0.236 mSv/MBq。
  • 肿瘤SUVmax范围0.2–4.7。
  • 共注射未标记JS001后脾摄取显著降低(P<0.05),肿瘤摄取和靶本比显著增加(P<0.05)。

临床怎么用

  • 124I-JS001 PET可用于评估肿瘤PD-1表达,PET/MR可能提高肝病灶检出率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although anti-programmed cell death molecule-1 (PD-1)/PD-1 ligand therapy has achieved remarkable success in oncology field, the low response rate and lack of accurate prognostic biomarker identifying benefiting patients remain unresolved challenges. This study developed a PD-1 targeting radiotracer 124I-labeled toripalimab (124I-JS001) for clinical PET imaging and evaluated its biodistribution, safety, and dosimetry in human. METHODS: Patients with melanoma or urologic cancer confirmed by pathology were enrolled. 124I-JS001 PET/CT and PET/MR were performed with or without coinjection of 5 mg unlabeled JS001, and 18F-FDG PET was undertaken within 1 week. RESULTS: Eight melanoma and 3 urologic cancer patients were enrolled. No adverse events were noticed during the whole examination after the injection of 124I-JS001 and an acceptable dosimetry of 0.236 mSv/MBq was found. 124I-JS001 PET/CT showed high uptake in spleen and liver and slight uptake in bone marrow and lung. All primary and metastatic tumor lesions in 11 patients demonstrated different levels of uptake of 124I-JS001 with SUVmax ranging from 0.2 to 4.7. With coinjection of unlabeled JS001, the uptake in spleen was reduced significantly (P < 0.05), whereas tumor uptake and tumor background ratio increased significantly (P < 0.05). Four patients undertook regional 124I-JS001 PET/MR. All tumor lesions were detected effectively with abnormal MR signal on PET/MR, whereas PET/MR detected liver lesions more sensitively than PET/CT. CONCLUSIONS: The first-in-human study demonstrated 124I-JS001 was a safe tracer for PET with acceptable dosimetry, and the PET/CT results showed a favorable biodistribution. PET/MR could detect liver lesions more sensitively than PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang S, Zhu H, Ding J, et al. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study. Clin Nucl Med. 2021. PMID: 33512952. doi:10.1097/RLU.0000000000003520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。